Caredx applauds district court decision to uphold jury verdict that natera falsely advertised its prospera transplant test

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the united states district court for the district of delaware (the “district court”) decision upheld and reaffirmed the march 2022 jury verdict finding that natera (nasdaq: ntra) violated the lanham act by falsely advertising.
CDNA Ratings Summary
CDNA Quant Ranking